Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1994-2000

  Chen, Guofang ^a,c   Nicula, Diana ^a   Renko, Kostja ^b   Derwahl, Michael ^a  

^a St Hedwig Hospital   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Anaplastic thyroid cancer; Cancer stem cells; Growth; Metformin; Sorafenib

Indexed keywords

METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DOXORUBICIN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE ARREST; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; ANALOGS AND DERIVATIVES; CARCINOMA; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; THYROID TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; METFORMIN; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPHEROIDS, CELLULAR; THYROID NEOPLASMS; TUMOR STEM CELL ASSAY;

EID: 84924912270     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3805     Document Type: Article

References (26)

1. Ordonez N, Baloch Z, Matias-Guiu X, et al: Undifferentiated (anaplastic) carcinoma. In: World Health Organization Classification of Tumours of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). IARC Press, Lyons pp77-80, 2004.
2. Smallridge RC, Marlow LA and Copland JA: Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16: 17-44, 2009.
3. Pasieka JL: Anaplastic thyroid cancer. Curr Opin Oncol 15: 78-83, 2003.
4. Granata R, Locati L and Licitra L: Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Curr Opin Oncol 25: 224-228, 2013.
5. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
6. Brose MS, Nutting CM, Jarzab B, et al: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384: 319-328, 2014.
7. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26: 4714-4719, 2008.
8. Haugen BR and Kane MA: Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab 95: 987-993, 2010.
9. Savvides P, Nagaiah G, Lavertu P, et al: Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23: 600-604, 2013.
10. Duntas LH and Bernardini R: Sorafenib: rays of hope in thyroid cancer. Thyroid 20: 1351-1358, 2010.
11. Chen G, Xu S, Renko K and Derwahl M: Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 97: E510-E520, 2012.
12. Zheng X, Cui D, Xu S, Brabant G and Derwahl M: Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: Characterization of resistant cells. Int J Oncol 37: 307-315, 2010.
13. Broecker M, Hammer J and Derwahl M: Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line. Life Sci 63: 2373-2386, 1998.
14. Manole D, Schildknecht B, Gosnell B, Adams E and Derwahl M: Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 86: 1072-1077, 2001.
15. Isakovic A, Harhaji L, Stevanovic D, et al: Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290-1302, 2007.
16. Lan L, Cui D, Nowka K and Derwahl M: Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes. J Clin Endocrinol Metab 92: 3681-3688, 2007.
17. Reddi HV, Madde P, McDonough SJ, et al: Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther 19: 659-665, 2012.
18. Thomas L, Lai SY, Dong W, et al: Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19: 251-258, 2014.
19. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
20. Salvatore G, De Falco V, Salerno P, et al: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-1629, 2006.
21. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW and Kapiteijn E: Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 167: 643-650, 2012.
22. Kim S, Yazici YD, Calzada G, et al: Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792, 2007.
23. Henderson YC, Ahn SH, Kang Y and Clayman GL: Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 14: 4908-4914, 2008.
24. Shen CT, Qiu ZL and Luo QY: Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a metaanalysis. Endocr Relat Cancer 21: 253-261, 2014.
25. Mitsutake N, Iwao A, Nagai K, et al: Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148: 1797-1803, 2007.
26. Ling S, Feng T, Ke Q, et al: Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep 31: 2611-2618, 2014.